Bright Minds Biosciences (DRUG) Current Assets (2020 - 2026)

Bright Minds Biosciences' Current Assets history runs 7 years deep, the most recent figure standing at $227.7 million for Q1 2026.

• Quarterly Current Assets rose 480.24% year-over-year to $227.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $227.7 million (up 480.24% YoY) and the FY2025 annual result came in at $61.3 million, up 1295.89% from the prior year.
• Current Assets was $227.7 million for Q1 2026 at Bright Minds Biosciences, up from $65.1 million in the prior quarter.
• Across five years, Current Assets topped out at $227.7 million in Q1 2026 and bottomed at $4.4 million in Q3 2024.
• A 5-year average of $35.2 million and a median of $8.4 million in 2022 frame the typical range for Current Assets.
• Annual changes were most pronounced in 2023 — Current Assets sank 44.53% — and 2025, when it jumped 1295.89%.
• Bright Minds Biosciences' Current Assets stood at $8.4 million in 2022, then sank by 40.34% to $5.0 million in 2023, then surged by 729.69% to $41.7 million in 2024, then soared by 56.2% to $65.1 million in 2025, then soared by 249.8% to $227.7 million in 2026.
• Business Quant data shows DRUG's Current Assets at $227.7 million in Q1 2026, $65.1 million in Q4 2025, and $61.3 million in Q3 2025.